PV Bulletin

Draft CVM GFI #256B - Compounding Animal Drugs from Bulk Drug Substances

The FDA has issued a draft guidance relating to the compounding of animal drugs from bulk drug substances, seeking public comments until November 27, 2026.

Primary source: Download the Draft Guidance Document

PV Impact Brief

Urgency: HighConfidence: high

What changed

The FDA has introduced draft guidance for compounding animal drugs from bulk drug substances, detailing enforcement policies for federally-registered facilities under CGMP standards.

Why it matters

This guidance provides essential information on compliance for veterinary facilities, impacting how animal drugs are compounded and ensuring adherence to safety standards, thereby protecting animal health.

Action needed

Comments on the draft guidance must be submitted by November 27, 2026. Facilities must comply with CGMP in accordance with specified enforcement policies to avoid potential enforcement actions.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 27, 2026

Full briefing

Practical implication

Comments on the draft guidance must be submitted by November 27, 2026. Facilities must comply with CGMP in accordance with specified enforcement policies to avoid potential enforcement actions.

The U.S. FDA has released a draft guidance document (CVM GFI #256B) on compounding animal drugs from bulk drug substances under current good manufacturing practices (CGMP) in federally-registered facilities. This draft is open for public comment and is not for implementation. Key aspects include compliance expectations for safety and quality standards in animal drug compounding.

What changed: The FDA has introduced draft guidance for compounding animal drugs from bulk drug substances, detailing enforcement policies for federally-registered facilities under CGMP standards.

Why it matters: This guidance provides essential information on compliance for veterinary facilities, impacting how animal drugs are compounded and ensuring adherence to safety standards, thereby protecting animal health.

Practical implication: Comments on the draft guidance must be submitted by November 27, 2026. Facilities must comply with CGMP in accordance with specified enforcement policies to avoid potential enforcement actions.

View original source

  • Source: FDA - Regulatory Information
  • Published at source: 2026-08-27T00:00:00.000Z
  • Discovered by monitor: 2026-08-27T22:07:17.026Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signals#Guidance#Source-ingestion#Regulator-monitor#Usa#Fda.gov

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward